stockrowWarby Parker Inc.
WRBY Healthcare Medical Instruments & Supplies
Warby Parker Inc.’s revenue for fiscal 2025 (year ended December 2025) was $871.9 million, up 13.0% from fiscal 2024.
- Revenue
- +10.4%
- EPS
- −20.0%
- Free cash flow
- −30.3%
Quarter to September 2026, against a year earlier
Follow WRBY
Alert me
Warby Parker Inc. (WRBY) Return on equity
Warby Parker Inc.'s return on equity over the twelve months to 30 September 2026 was 1.93%, up 1.5 percentage points from fiscal 2025 (0.46%). Over the past ten years it has ranged from −358.2% (fiscal 2021) to 29.7% (fiscal 2019); the current reading is higher than 71% of that period. That is above the Medical Instruments & Supplies industry median of 0.00% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 0.46% | 6.81 |
| FY2024 | −6.35% | 15.13 |
| FY2023 | −21.5% | 17.08 |
| FY2022 | −38.6% | 319.59 |
| FY2021 | −358.2% | (387.01) |
| FY2020 | 28.9% | (0.83) |
| FY2019 | 29.7% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| LMAT LeMaitre Vascular, Inc. compare | 15.6% |
| STVN Stevanato Group S.p.A. compare | 9.22% |
| ATRC AtriCure, Inc. compare | 2.95% |
| ICUI ICU Medical, Inc. compare | 2.79% |
| WRBY Warby Parker Inc. | 1.93% |
| AZTA Azenta, Inc. compare | −7.72% |
| XRAY DENTSPLY SIRONA Inc. compare | −8.55% |
| PLSE Pulse Biosciences, Inc compare | −60.7% |
| KMTS Kestra Medical Technologies, Ltd. compare | −73.7% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on WRBY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement